Recent studies showed that plasma tau phosphorylated at threonine 181 (p-tau181) can identify people with AD dementia, distinguish Aβ positive from Aβ negative individuals, and predict future dementia with a degree of accuracy that is comparable to the predictive accuracy of established AD biomarkers [6]. This evidence concerns the gene MAPT and Alzheimer disease.